New analyses presented at CHEST bring a differing perspective to the debate surrounding adaptive servo ventilation device therapy in patients with heart failure with reduced ejection fraction and central sleep apnea, reports MD Magazine.
In assessing the sole treatment of CSA with SRV in patients with both the sleeping disorder and HFrEF, Saraf and his team pulled from a pre-established population of patients at the university’s Sleep Heart Program. They compared mortality between ASV-treated HFrEF-CSA patients, and patients who previously did not accept positive airway pressure (PAP) therapy.
